NGL FINECHEM
|
NGL FINECHEM Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 33.80 | 66.63 | 33.04 | 80.68 | 91.58 |
| CEPS(Rs) | 54.35 | 85.72 | 51.45 | 97.55 | 105.30 |
| DPS(Rs) | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
| Book NAV/Share(Rs) | 457.16 | 425.11 | 360.23 | 328.94 | 250.01 |
| Tax Rate(%) | 23.78 | 24.07 | 25.09 | 25.08 | 26.90 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.45 | 15.87 | 12.57 | 21.48 | 31.05 |
| EBIT Margin(%) | 8.41 | 16.60 | 10.50 | 21.58 | 30.93 |
| Pre Tax Margin(%) | 7.53 | 16.07 | 9.84 | 20.98 | 30.08 |
| PAT Margin (%) | 5.74 | 12.20 | 7.37 | 15.72 | 21.99 |
| Cash Profit Margin (%) | 9.12 | 15.64 | 11.43 | 18.98 | 25.22 |
| Performance Ratios | |||||
| ROA(%) | 5.36 | 12.86 | 7.27 | 20.61 | 31.42 |
| ROE(%) | 7.75 | 17.03 | 9.63 | 27.90 | 44.76 |
| ROCE(%) | 9.44 | 20.38 | 11.96 | 33.91 | 53.53 |
| Asset Turnover(x) | 0.93 | 1.05 | 0.99 | 1.31 | 1.43 |
| Sales/Fixed Asset(x) | 2.02 | 2.36 | 2.07 | 2.82 | 2.75 |
| Working Capital/Sales(x) | 3.16 | 2.69 | 2.66 | 2.94 | 3.12 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.50 | 0.42 | 0.48 | 0.36 | 0.36 |
| Receivable days | 84.83 | 83.78 | 85.22 | 58.36 | 45.10 |
| Inventory Days | 46.87 | 37.88 | 54.47 | 53.95 | 46.51 |
| Payable days | 106.96 | 85.07 | 75.67 | 72.38 | 78.66 |
| Valuation Parameters | |||||
| PER(x) | 32.97 | 31.37 | 36.22 | 24.27 | 16.74 |
| PCE(x) | 20.51 | 24.38 | 23.26 | 20.07 | 14.56 |
| Price/Book(x) | 2.44 | 4.92 | 3.32 | 5.95 | 6.13 |
| Yield(%) | 0.16 | 0.08 | 0.15 | 0.09 | 0.11 |
| EV/Net Sales(x) | 2.06 | 3.91 | 2.73 | 3.90 | 3.72 |
| EV/Core EBITDA(x) | 17.50 | 19.50 | 18.74 | 15.70 | 10.88 |
| EV/EBIT(x) | 24.53 | 23.54 | 25.99 | 18.08 | 12.02 |
| EV/CE(x) | 2.11 | 4.46 | 2.98 | 4.47 | 4.62 |
| M Cap / Sales | 1.87 | 3.81 | 2.66 | 3.81 | 3.67 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.73 | 21.80 | -12.42 | 23.08 | 70.07 |
| Core EBITDA Growth(%) | -36.02 | 67.63 | -48.67 | -10.49 | 286.35 |
| EBIT Growth(%) | -44.92 | 92.58 | -57.38 | -14.14 | 442.89 |
| PAT Growth(%) | -48.87 | 101.58 | -58.92 | -12.03 | 580.47 |
| EPS Growth(%) | -49.27 | 101.66 | -59.05 | -11.91 | 597.04 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.27 | 0.13 | 0.15 | 0.15 | 0.11 |
| Current Ratio(x) | 1.98 | 2.46 | 2.79 | 2.64 | 2.98 |
| Quick Ratio(x) | 1.55 | 1.96 | 2.33 | 1.79 | 2.08 |
| Interest Cover(x) | 9.51 | 31.07 | 15.92 | 35.81 | 36.21 |
| Total Debt/Mcap(x) | 0.11 | 0.03 | 0.04 | 0.02 | 0.02 |
Compare Financial Ratios of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹814.1 Cr | -2% | -19.5% | -28.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,068.0 Cr | -0.2% | 7.1% | 1.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,847.0 Cr | 0.8% | -6% | 4.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹127,985.0 Cr | 1.2% | 6.4% | 13.1% | Stock Analytics | |
| CIPLA | ₹122,826.0 Cr | -0.2% | 1.4% | -0.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,418.0 Cr | 1.2% | 5.8% | 4.2% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -2% |
-19.5% |
-28.3% |
| SENSEX | 0% |
2.7% |
6.8% |
You may also like the below Video Courses